Anti-CD33 chimeric antigen receptor T cell therapy (Shanghai YaKe/Zhejiang University)

N/A

Report date: 2025/04/03 14:47:35

Base Information

Drug NameAnti-CD33 chimeric antigen receptor T cell therapy (Shanghai YaKe/Zhejiang University)
Drug Alias NameCD33 CAR-T cell therapy
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-Myeloid cell surface antigen CD33
TargetsMyeloid cell surface antigen CD33
Therapy Area/IndicationsLeukemia, Myeloid, Acute
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai YaKe Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai YaKe Biotechnology Co LtdZhejiang University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A